Leaders at Bristol-Myers Squibb Company and Pfizer Inc. plan to present 19 different abstracts related to the Eliquis treatment at this year’s ESC Congress, located in Rome, Italy.
The 19 abstracts feature new post-hoc sub-analyses from the latest ARISTOTLE phase III trial, as well as several retrospective real-world data analyses from the most recent ACROPOLIS.
“The Bristol-Myers Squibb and Pfizer Alliance is pleased to share 19 abstracts, which include new real-world analyses, as well as new sub-analyses from the pivotal phase III ARISTOTLE trial,” Dr. Rory O’Connor, chief medical officer for Internal Medicine, Pfizer Innovative Health, said. “We look forward to the opportunity to contribute to the scientific discussion and continued research during ESC Congress 2016.”
ARISTOTLE, Apixaban for Reduction In Stroke and Other Thromboembolic Events, will demonstrate the Alliance’s dedication to determining whether Eliquis is safe for patients. ACROPOLIS, Apixaban Experience Through Real-World Population Studies, will also help to find the safety and efficacy of apixaban for routine clinical practices.
“As patient and provider needs continue to evolve, it’s essential that we deepen our understanding of how medicines are working in real-world situations,” Dr. Jack Lawrence, vice president of cardiovascular specialty development at Bristol-Myers Squibb, said. “This year at ESC Congress 2016, we’ll be discussing new NVAF and VTE data that complement our robust body of clinical trial data.”
